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Substance misuse in patients who have comorbid chronic pain in a clinical 
population receiving methadone maintenance therapy for the treatment of 
opioid dependence 
 
Abstract 
Aims 
To compare specific substance misuse in treatment-seeking, opioid-dependent patients with and 
without comorbid chronic pain, and to assess the respective value of urinalysis and patient reports in 
assessing substance misuse. 
 
Methods 
Participants comprised a clinical population in a regional NHS Substance Misuse Service in the East of 
Scotland (N=521).  The Brief Pain Inventory – Short Form was used to assess pain and the Maudsley 
Addiction Profile and urinalysis were used to assess substance misuse at study inception.  Urinalysis 
was used to assess substance misuse during the 5-year follow-up period.  Data were hosted, linked, 
anonymised and analysed within a national Safe Haven. 
 
Results 
Compared with opioid-dependent patients with no pain, a significantly higher proportion of 
treatment-seeking, opioid-dependent patients with chronic pain were engaged in non-medical 
benzodiazepine use (69% versus 58%; p=0.016) and illicit cannabinoid use (84% versus 65%; 
p=0.025) at study inception.  Furthermore, a significantly higher proportion of this group was shown 
to continue non-medical benzodiazepine use (70% versus 42%; p=0.037) and illicit cannabinoid use 
(100% versus 31%; p=0.002) during the 5-year follow-up period.  There were significant correlations 
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between drug screen results and patient-reported use of opioids (Tetrachoric ϱ=0.4944; p<0.001), 
benzodiazepines (Tetrachoric ϱ=0.2641; p=0.001) and cannabinoids (Tetrachoric ϱ=0.8384; p<0.001). 
 
Conclusions 
Whilst gaining control of illicit opioid use during treatment, opioid-dependent patients with 
comorbid chronic pain demonstrated persistent problematic use of benzodiazepines and 
cannabinoids.  This pattern of misuse was shown to persist during the 5-year follow-up period. 
 
Keywords: Opioid agonist therapy; methadone maintenance therapy; opioid 
dependence; chronic pain; and illicit substance use. 
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1.1 Introduction 
Chronic pain is highly prevalent in treatment-seeking, opioid-dependent populations with between 
36% and 68% affected (Barry et al., 2013; Tsui et al., 2016).  Thus, chronic pain is an important 
clinical condition to be considered by addiction specialists.  Furthermore, patients in receipt of 
opioid agonist therapy (OAT) who have comorbid chronic pain are associated with relatively poor 
health and substance use treatment outcomes, further complicating the delivery of effective 
treatment in substance misuse services.  This comorbid presentation is associated with a range of 
medical and psychiatric morbidities (Iskandar et al., 2013; O’Toole et al., 2013), in addition to 
relatively severe and enduring substance misuse problems (Dunn et al., 2014; Larson et al., 2007).  In 
addressing this issue, many studies have focused on any substance misuse (rather than specific drug 
misuse) as the target variable (e.g. Caldeiro et al., 2008) or illicit opioid use versus any other 
substance misuse (Dennis  et al., 2015); however, there is a need to understand specific drug misuse 
profiles in this comorbid population to identify any patterns or problems with specific substances.  
Only then can further research explore the potential causes of the high levels of drug misuse in this 
comorbid group and work towards effective treatment delivery in substance misuse services. 
 
OAT programmes focus on a range of health-related and functional outcomes but the core outcomes 
are considered to be retention in treatment and control over substance use (Kidd et al., 2013).  
These two core aims are considered to lead to decreased mortality (Cousins et al., 2016), drug-
related harm reduction (Hutchinson et al., 2000; Nolan et al., 2014), increased health and 
functioning (Bart, 2012; Quednow & Herdener, 2016), and crime reduction (Hutchinson et al., 2000; 
Russolillo et al., 2018).  A number of studies have compared substance misuse outcomes in patients 
with and without comorbid chronic pain; however, they have tended to focus on any substance 
misuse, rather than attempting to profile use of specific substances (Caldeiro et al., 2008; Dennis et 
al., 2015).  Barry and colleagues (2009) undertook a cross-sectional study examining illicit substance 
use in 150 methadone-maintained patients with and without clinically-significant pain (CSP).  CSP 
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was defined as pain having persisted for at least 6 months with moderate-severe intensity or 
significant pain interference.  The control group reported no pain in the 7 days preceding 
assessment.  The most commonly-reported substance misuse concerned illicit use of cocaine (25%), 
cannabinoids (11%), heroin (11%), and nonmedical use of benzodiazepines (11%); however, there 
were no significant group differences.  In a more recent study, Dunn and colleagues (2014) examined 
the predictive capacity of pain on urinalyses in a methadone-maintained clinical population.  Pain 
was significantly associated with mean percent of benzodiazepine-positive urine samples, but was 
not associated with opioid- or cocaine-positive samples. 
 
A further concern in treatment-seeking, opioid-dependent populations is the extent of problematic 
substance use – the amount of drug consumption, duration of drug use and frequency of drug use.  
Trafton and colleagues (2004) examined frequency and duration of illicit substance use in a sample 
of 251 veterans attending eight ORT treatment facilities who were in receipt of either methadone or 
levo-alpha-acetyl-methadol (LAAM).  They reported that, on entry to treatment, patients with pain 
had used illicit substances more frequently than patients with no pain in the preceding 30 days and 
for longer durations during their lifetimes.  This finding related specifically to substances associated 
with potential analgesic effects.  Increased frequency of illicit opioid used was noted in patients with 
pain in the preceding 30 days (2.3 versus 0.8 days in patients with no pain) and increased duration 
during their lifetimes (2.9 versus 0.9 years in patients with no pain).  Increased frequency of illicit 
cannabinoid use was noted in patients with pain in the preceding 30 days (2.8 versus 0.8 days in 
patients with no pain) and increased duration during their lifetimes (10.3 versus 7.5 years in patients 
with no pain).  Increased duration of nonmedical sedative use during their lifetimes was noted in 
patients with pain (2.5 versus 0.4 years in patients with no pain).  There were no group associations 
with alcohol, cocaine, heroin or poly-substance use.  Information concerning duration of pain 
symptoms were not available; therefore, one limitation of the study was that the authors were 
unable to distinguish between chronic and acute pain on entry to treatment. 
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Whilst gaining a cross-sectional understanding of illicit substance use on entry to treatment is of 
some clinical relevance, examining response to OAT treatment in the longer term is of key 
importance to policy development and effective healthcare delivery.  Caldeiro and colleagues (2008) 
examined abstinence at 12-month follow-up of 582 patients in a Veterans Affairs (VA) outpatient 
addiction treatment facility.  Assessment of pain characteristics in the cohort resulted in the 
identification of three groups: low pain (n=114); intermittent pain (n=275); and persistent pain 
(n=193).  The proportion of abstinence from illicit drug use was similar across all three groups at 
baseline; however, persistent pain was associated with a poorer outcome at 12-month follow-up.  
There was a significant stepwise relationship between pain group and abstinence at follow-up, with 
the highest proportion of abstinence found in the ‘low pain’ group (58%) and the lowest proportion 
found in the ‘persistent pain’ group (44%). 
 
Effective management of substance misuse problems in patients with comorbid chronic pain is 
dependent upon understanding the particular profiles and the longer-term trajectories of drug 
misuse (Sheu et al., 2008).  Several studies report ‘long-term’ follow-up over 12 months (e.g. 
Caldeiro et al., 2008; Ilgen et al., 2006).  In this treatment group, however – which is characterised 
by problems that persist for years or even decades – 12 months may be considered to be a relatively 
short duration.  The aims of the present study are two-fold.  First, to compare specific common 
drugs of misuse at study inception in methadone-maintained patients with and without chronic pain.  
Secondly, to compare misuse of the same substances in these two groups at 5-year follow-up.  
Continuation and initiation of illicit drug use were considered separately from each other 
since initiation of illicit drug use after commencing treatment may present different clinical 
challenges compared with continuation of illicit drug use despite treatment. 
 
1.2 Methods 
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1.2.1 Participants and setting 
Participants comprised methadone-maintained patients attending a National Health Service (NHS) 
substance misuse service in the East of Scotland.  All participants were clinically-diagnosed as being 
dependent upon opioids – primarily heroin (as reported by the service) – on entry to treatment 
(using the World Health Organisation's International Classification of Diseases (ICD) diagnostic 
criteria), and many were also engaged in polysubstance abuse.  A case-control design was employed; 
cases were treatment-seeking, opioid-dependent patients with comorbid chronic pain and controls 
were treatment-seeking, opioid-dependent patients with no pain.  Three temporal thresholds have 
been established to identify chronic pain: 3 months; 6 months; and 12 months (Smith & Torrance, 
2008).  In the present study the chronicity threshold was set at 12 months; the rationale for 
employing this threshold was that, in a clinical population familiar with persistent, debilitating 
conditions, the highest conventional threshold was considered to facilitate the best comparison 
between truly ‘chronic’ pain and no pain. 
 
1.2.2 Materials 
Sociodemographic data were collected at study inception using a proforma developed by the NHS 
treatment service.  Data were collected using an interview format and the proforma recorded: age; 
gender; 3 accommodation-related questions; 7 questions concerning dependent children; 12 health-
related questions; 3 education-related questions; and 2 questions concerning support from other 
agencies.  Scores on the Scottish Index of Multiple Deprivation (SIMD) data were provided for all 
participants by the Safe Haven.  Participants were then assigned to SIMD quintiles, whereby, Q1-Q2 
represented relative deprivation and Q3-Q5 represented relative affluence. 
 
A service-modified version of the Brief Pain Inventory – Short Form (BPI-SF; Cleeland & Ryan, 1994) 
was used to identify and profile the severity and impact of pain at study inception.  The BPI-SF is a 9-
item questionnaire intended to assess the sensory and reactive dimensions of pain.  The BPI-SF has 
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been validated in a number of clinical populations, including patients in receipt of methadone 
maintenance therapy for the treatment of opioid dependence (Dennis et al., 2016).  One of the 
modifications was the addition of a question asking duration of pain (in months or years and 
months) at study inception. 
 
A service-modified version of the Maudsley Addiction Profile (MAP; Marsden et al., 1998) was used 
to obtain information on substance misuse at study inception.  The MAP is a 60-question, clinician-
administered instrument designed for research purposes and used in investigations of populations 
with drug and/or alcohol problems.  Reliability and validity of the MAP have been demonstrated in 
substance misusers (Keary et al., 2012). 
 
An electronic regional extract of the nationally-held NHS Scotland biochemical laboratory test 
dataset provided drug screen results.  This dataset was used to identify all positive and negative 
results for the presence in the urine of opioids, benzodiazepines and cannabinoids (the three most 
commons drugs of abuse in this particular treatment service). 
 
1.2.3 Procedure 
The study was incepted at the beginning of 2005, and follow-up data were collected at routine 
intervals during the five year follow-up period (2005-2010).  The BPI-SF instruments were completed 
at routine weekly clinic appointments with specialist addiction nurses at study inception.  Staff were 
trained on administration of these instruments, to ensure uniformity in data collection procedures.  
Participants were excluded from the study if no BPI-SF was completed or if duration of pain at study 
inception was not recorded, since it was not possible to determine if their pain was ‘chronic’. 
 
Urine samples were intended to be collected 3-monthly during the follow-up period and underwent 
biochemical testing.  The follow-up biochemical data were dependent, however, upon urine samples 
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having been obtained in the clinic setting.  The NHS treatment service aims to undertake drug 
screens, by urinalysis, every three months with each patient.  The amount of missing data indicates 
that this was not achieved for all patients.  Urinalysis is associated with a relatively high risk of false-
positive and false-negative results (Marsden et al., 1998; Nelson et al., 2016; Riahi-Zanjani, 2014; 
Saitman et al., 2014).  In the present study, therefore, illicit drug use was concluded where there 
were at least three positive test results in a 12-month period.  These data were obtained for the 12-
month period at study inception (calendar year 2005) and the 12-month period at 5-year follow-up 
(calendar year 2010). 
 
MAP data were obtained at study inception only, during routine weekly clinic appointments with 
specialist addiction nurses at study inception.  Staff were trained on the administration of these 
instruments, to ensure uniformity in data collection procedures.  Substance misuse data were 
extracted from the MAP in binary form so as to facilitate comparisons with the urinalysis findings. 
 
Biochemical laboratory data were obtained and hosted by one of the national Safe Havens, where 
they were electronically-linked to the data collected at the NHS treatment service.  All data were 
anonymised within the Safe Haven prior to release to the research team and statistical analyses 
were undertaken within this secure virtual environment. 
 
1.2.4 Statistical considerations 
The Statistical Package for Social Scientists (SPSS v22) was used to undertake statistical testing.  
Statistical findings are reported as chi-square value and degrees of freedom (χ2(df)), probability 
value (p) and effect size, Pearson’s Phi or Cramer’s V (ω).  Pearson’s Phi was used to assess the effect 
size in 2x2 contingency tables and Cramer’s V was used where there were more than two levels in 
independent variables.  Descriptive summary data are presented as number of event (n) and 
percentage of group (%).  For univariate analysis of variance (ANOVA) findings are reported as F 
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value, between-subjects degrees of freedom and within-subjects degrees of freedom (F(between-
subjects df, within-subjects df)), probability value (p) and effect size, partial eta squared (
2
p ).  
Descriptive summary data are presented as mean value (
_
x ) and standard deviation around the mean 
(σ).  Maximum likelihood Tetrachoric correlation coefficients were undertaken, using Stata v14, to 
provide rho estimates of the correlation between patient-reported illicit substance use and urinalysis 
results.  Findings are reported as the Tetrachoric rho (ϱ), the standard error (σ) and the probability 
value (p). 
 
1.2.5 Ethical considerations 
Ethical approval was not required for the present study, since all data were anonymised and 
accessed via a national Safe Haven; however, a favourable ethical opinion was obtained from the 
East of Scotland Research Ethics Committee (EoSREC). 
 
1.3 Results 
1.3.1 Representativeness of study cohort 
Assessment of demographic, socioeconomic, educational, health and personal characteristics 
revealed that the study cohort (n=521) was broadly representative of the entire treatment 
population (n=626).  A significantly greater proportion of those that were excluded due to missing 
data comprised patients that were: relatively affluent; living in urban locations; and associated with 
fewer physical health problems. 
 
1.3.2 Group identification, clinical profile of chronic pain and therapeutic methadone dose at study 
inception 
Of the 521 patients that completed a full pain assessment, 54 (11%) were excluded from analysis as 
they reported pain duration of less than 12 months.  Just over half of the remainder (n=246; 53%) 
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were identified as having comorbid chronic pain (cases, referred to as the ‘CP group’), whilst 221 
(47%) reported no pain at study inception (controls, referred to as the ‘NoP group’).  Not all 
participants answered all questions on the BPI-SF and, in consequence, percentages were calculated 
in respect of the number having responded to each question.  Patients with chronic pain reported a 
mean duration of pain of 99 months (SD=88; median=72; range=12-550).  On a 0-100 scale these 
patients reported a mean pain intensity of 63 (SD=21; median=65; range=4-100).  Almost a quarter 
(24%, n=58) reported pain at multiple sites (i.e. two or more sites), 70% (n=173) reported pain 
interference in daily activities and 80% (n=197) reported sleep interference as a consequence of 
pain.  More than three quarters (79%, n=175) had attended a physician for treatment of their pain 
and, of those, 41% (n=75) were treated by a pain specialist.  Just over half of those treated by a 
physician (59%, n=113) felt that their pain problem had been taken seriously.  Just over half (56%, 
n=114) were in receipt of an analgesic prescription with 22% (n=45) of them having been in receipt 
of an opioid analgesic prescription, in addition to methadone prescribed as OAT for the treatment of 
opioid dependence.  The CP group was in receipt of a significantly higher methadone dose of 
methadone (F(1,419)=4.370; p=0.037 (
2
p =0.010)).  The mean daily dose of the CP group (55mg; 
σ=24) was more than double that of the NoP group (25mg; σ=25). 
 
1.3.3 Demographic and socioeconomic characteristics of patients with chronic pain and without pain 
at study inception 
The two groups had very similar demographic profiles.  Almost three quarters of each group was 
male and around 90% of each group was living in areas of high socioeconomic deprivation (SIMD 
quintiles 1 and 2).  The CP group was significantly older (35 years; SD=7.5) than the NoP group (32 
years; SD=7.9) by a mean difference of just under 3 years (F(1,428)=14.980; p<0.001). 
 
1.3.4 Illicit substance use in patients with and without chronic pain at study inception 
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Misuse of opioids, benzodiazepines and cannabinoids is shown in Table 1.  Patient-reported use is 
shown in the first half of the table and urinalysis results are shown in the second half of the table.  
Patient-reported illicit opioid use included heroin, methadone and other opioid analgesics; however, 
in consequence of all patients having been in receipt of prescription methadone, biochemical drug 
screens for illicit opioid use did not include screening for methadone. 
 
[Insert Table 1 around here] 
 
Table 1 shows that there was no significant difference between groups in their use of opioids with 
more than half of each group reporting illicit use.  A statistically significant correlation was found 
between patient-reported illicit opioid use and urinalysis results (Tetrachoric ϱ=0.4944; σ=0.0636; 
p<0.0001).  Urinalysis identified slightly fewer positive results than expected, based on patient 
reports. 
 
There was a statistically significant correlation found between patient-reported illicit benzodiazepine 
use and urinalysis results (Tetrachoric ϱ=0.2641; σ=0.0770; p=0.0011).  Patient reports indicated no 
group difference with around a third of each group reporting illicit use of benzodiazepines.  There 
were, however, many who denied nonmedical benzodiazepine use, despite this having been found 
on urinalysis, particularly in the CP group.  Urinalysis revealed that a significantly higher proportion 
of the CP group generated positive benzodiazepine results. 
 
There was a statistically significant correlation found between patient-reported illicit cannabinoid 
use and urinalysis results (Tetrachoric ϱ=0.8384; σ=0.0736; p<0.0001).  Both patient reports and 
urinalyses revealed that a significantly higher proportion of the CP group was engaging in illicit 
cannabinoid use. 
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1.3.5 Illicit substance use during the 5-year follow-up period 
A significantly higher proportion of the CP group (n=160; 65%) was retained in treatment compared 
with the NoP group (n=105; 48%).  Of those not retained, a significantly higher proportion of the CP 
group (n=26; 30%) was deceased at follow-up compared with the NoP group (n=13; 11%).  The 
survivor bias (or ‘survivor effect’) should be borne in mind when interpreting the remainder of the 
findings, since the patients that died would have been likely to have had more problems and poorer 
health.  The effect of the survivor bias, in this context, would be an underestimation of problems and 
an overestimation of wellbeing, particularly in the CP group.  In consequence, there would be a 
muting of group differences in cases where the CP group was associated with poorer outcomes. 
 
Chi square was used to analyse change in results between study inception and follow-up.  
Continuation and initiation of illicit drug use were considered separately from each other since 
initiation of illicit drug use after commencing treatment may present different clinical challenges 
compared with continuation of illicit drug use despite treatment.  Continuation of illicit drug use was 
compared to cessation during the follow-up period, and initiation of illicit drug use was compared to 
no use at study inception or at follow-up.  Findings are reported in Table 2. 
 
[Insert Table 2 around here] 
 
Table 2 shows that a significantly higher proportion of the NoP group than the CP group continued 
illicit opioid use during the 5-year follow-up period; however, there was no significant group 
difference in the initiation of illicit opioid use during the follow-up period.  Conversely, a significantly 
higher proportion of the CP group than the NoP group continued use of benzodiazepines and 
cannabinoids.  There was no significant group difference in the initiation of non-medical 
benzodiazepine use and there were insufficient data to test for group differences in the initiation of 
illicit cannabinoid use during the follow-up period. 
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1.4 Discussion 
The aim of the present study was to compare problematic substance use in treatment-seeking, 
opioid-dependent patients with and without comorbid chronic pain.  Comparisons were undertaken 
at study inception and at 5-year follow-up.  The prevalence of chronic pain in this population in 
receipt of OAT was found to be 53%.  There were no differences between those with and those 
without chronic pain in their illicit opioid use at study inception; however, significantly higher 
proportions of the group with comorbid chronic pain were engaged in non-medical benzodiazepine 
use and illicit use of cannabinoids.  Continuation of illicit opioid use was significantly elevated in the 
group with no pain, whilst continuation of benzodiazepine and cannabinoid use was significantly 
elevated in the comorbid pain group. 
 
Biochemical drug screen results are generally preferred to patient-reported drug use (Li et al., 2017); 
however, there are advantages associated with patient-reported data.  First, it is possible to obtain 
information concerning the amount used and the routes of administrations.  Secondly, in 
methadone-maintained populations, due to the need to control for prescribed methadone, it is not 
possible to include methadone in screens for illicit opioid use.  Indeed, in the present study, 
urinalysis identified slightly fewer positive results than expected, based on patient reports, and this 
disparity may be due to the absence of methadone screens.  The general preference for biochemical 
drug screen results is based on concerns around the respective validity of the two methods of data 
collection, as discussed by Li and colleagues (2017).  Similar to the findings of their study, the 
present study found statistical correlations between patient reports and urinalysis findings for all 
drugs examined.  This finding requires further replication, which may highlight the potential value of 
the inclusion of patient-reported drug use in future studies. 
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A significantly higher proportion of the group with no pain reported illicit heroin use; however, this 
finding was not corroborated by opioid drug screen results.  This may be a result of urinalysis not 
screening, specifically, for heroin; therefore, opioid screens also included illicit use of opioid 
analgesics, but not methadone.  Alternatively, this finding may be an artefact of the short half-life of 
heroin (~30 minutes for a single dose) and the time between drug use and testing, resulting in 
patient-reported heroin use but negative urinalysis findings, further highlighting the potential value 
of patient-reported data.  A significantly higher proportion of this group continued illicit opioid use 
during the follow-up period.  Heroin is the primary drug of abuse in most patients entering this 
particular OAT programme and, as such, is the principal drug of concern when assessing response to 
treatment.  Furthermore, negative opioid drug screens are often a requirement in OAT programmes 
for continued treatment delivery.  This finding may reflect efforts in the comorbid pain group to 
conform to treatment agreements or it may reflect relative instability in patients with no pain. 
 
Significantly higher proportions of the comorbid pain group were engaged in nonmedical 
benzodiazepine use and illicit cannabinoid use at study inception, and significantly higher 
proportions continued use of both drugs during the follow-up period.  The denial of urinalysis-
verified benzodiazepine use may reflect substantial use of benzodiazepines other than diazepam or 
may reflect efforts to conceal nonmedical use of benzodiazepines in both groups, but particularly in 
the comorbid pain group.  Benzodiazepines are frequently used in conjunction with heroin or other 
opioids to intensify the euphoric experience (Jones et al., 2012); as such, benzodiazepine use may be 
viewed as part of the profile of ‘problematic drug use’ and patients may feel a need to conceal its 
use.  This finding highlights the value in using objective measures of substance use to corroborate 
patient reports.  Alternatively, misuse of these drugs may reflect attempts to control unmanaged 
symptoms.  The analgesic properties of cannabinoids are well-documented (Elikottil et al., 2009; 
Lotsch et al., 2018; Manzanares et al., 2006), and benzodiazepines can be used as an adjunct to 
analgesia or as a muscle relaxant as part of a pain management regimen.  As such, patients may use 
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these drugs to control unmanaged pain.  Furthermore, this profile of drug use is commonly 
associated with patients with psychiatric problems (Brunette et al., 2003; Diehl et al., 2010; Grattan 
et al., 2012).  Psychiatric morbidity is known to be highly prevalent in both opioid-dependent 
patients (Ardakani et al., 2013; Roncero et al., 2016) and in patients with pain problems (de Heer et 
al., 2014; Woo, 2010) and, therefore, may be amplified in comorbid populations (Dhingra et al., 
2013; Fox et al., 2012).  These findings may reflect under-treatment for psychiatric distress which 
results in ‘chaotic’ lifestyles and behaviours and, in opioid-dependent patients, this may manifest as 
uncontrollable substance use problems.  Future studies should consider the role of pain and 
psychiatric morbidity when examining problematic substance use in opioid-dependent populations. 
 
1.4.1 Limitations 
A key limitation of the present study is that pain assessments were undertaken at study inception 
only and not at follow-up.  This may have resulted in a degree of misclassification at follow-up, since 
some patients may have developed chronic pain during the observation period and, indeed, some 
may have recovered.  Furthermore, as a result of the limited statistical tests available for analysing 
binary data, only two time-points were observed – study inception and 5-year follow-up.  It would 
have been interesting to have been able to compare across each of the years during the observation 
period.  Our definition of illicit drug use (three positive drug tests in a 12-month period) was 
conservative to avoid misclassification arising through false positive tests.  A less stringent definition 
would have identified higher proportions, but would also likely have included some who were 
identified inappropriately.  There is no agreed definition of illicit drug use based on urine testing, and 
ours may have resulted in the under-identification of drug misuse.  It should be noted that the data 
are 8 years old.  Whilst they are likely to be relevant currently, it is possible that drug use profiles 
may have changed slightly due to drug availability in this specific geographic location.  Finally, there 
was a significant group difference in terms of age; whilst this may represent statistical significance, 
the mean difference of almost three years may be considered to be of minimal clinical relevance. 
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1.4.2 Conclusions 
Patients attending an OAT service who have chronic pain were shown to be more likely to misuse 
benzodiazepines and cannabinoids, but not opioids, than those without pain.  This pattern of drug 
use was shown to persist in this group over the 5-year follow-up period.  The role of unmanaged 
pain and psychiatric morbidity should be examined further, and future studies should acknowledge 
the potential corroborative and elucidation value of using both patient reports and drug screen 
results when assessing substance misuse. 
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Table 1: Group differences in patient-reported substance use in the 28 days prior to study inception 
and biochemical drug screen results at study inception.  [Prescription medication was controlled in 
analyses of biochemical drug screen results.] 
         CP       NoP 
  N % N % 
 
Patient-reported illicit opioid use χ2(1)=1.814; p=0.178 (ω=0.067) 
 Yes 111 52 110 59 
 No 102 48 77 41 
 
Patient-reported illicit heroin use χ2(1)=3.283; p=0.044 (ω=0.090) 
 Yes 86 40 92 49 
 No 128 60 95 51 
 
Patient-reported illicit diazepam use χ2(1)=0.029; p=0.475 (ω=0.008) 
 Yes 73 34 62 33 
 No 142 66 125 67 
 
Patient-reported illicit cannabis use χ2(1)=8.037; p=0.003 (ω=0.142) 
 Yes 172 81 128 68 
 No 41 19 59 32 
 
Positive biochemistry opioid results χ2(1)=2.537; p=0.067 (ω=0.076) 
 Yes 106 47 114 55 
 No 120 53 95 45 
 
Positive biochemistry benzodiazepine results χ2(1)=5.062; p=0.016 (ω=0.108) 
 Yes 153 69 121 58 
 No 70 31 87 42 
 
Positive biochemistry cannabinoid results χ2(1)=4.720; p=0.025 (ω=0.210) 
 Yes 46 84 34 65 
 No 9 16 18 35 
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Table 2: Changes in urine drug screen results between study inception and 5-year follow-up. 
Urine biochemistry results for illicit substance use        CP       NoP 
N % N % 
 
Opioids: positive results at inception χ2(1)=5.237; p=0.027 (ω=0.411) 
 Continuation of use during the follow-up period 5 36 13 77 
 Cessation of use during the follow-up period 9 64 4 23 
 
Benzodiazepines: positive results at inception χ2(1)=4.268; p=0.037 (ω=0.289) 
 Continuation of use during the follow-up period 19 70 10 42 
 Cessation of use during the follow-up period 8 30 14 58 
 
Cannabinoids: positive results at inception χ2(1)=9.692; p=0.002 (ω=0.679) 
 Continuation of use during the follow-up period 8 100 4 31 
 Cessation of use during the follow-up period 0 0 9 69 
 
Opioids: negative results at inception χ2(1)=0.134; p=0.459 (ω=0.047) 
 Initiation of use during the follow-up period 15 45 11 41 
 No use at study inception or follow-up 18 55 16 59 
 
Benzodiazepines: negative results at inception χ2(1)=2.694; p=0.103 (ω=0.290) 
 Initiation of use during the follow-up period 14 78 7 50 
 No use at study inception or follow-up 4 22 7 50 
 
Cannabinoids: negative results at inception Not computed 
 Initiation of use during the follow-up period 0 0 0 0 
 No use at study inception or follow-up 2 100 1 100 
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better off focusing on issues that can be directly tied to the data collected for the purpose 
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explanations for, and implications of these. 
  
 24.)    The Limitations section of the Discussion needs work. I can think of a number of 
other limitations that are worthy of inclusion: 1.) the use of only two time points as 
opposed to looking at substance use over multiple time points during the 5-year interval, 
2.) issues of generalizability mentioned in Comment 16, and 3.) power issues mentioned in 
Comment 17. 
RESPONSE: The Limitations section has now been rewritten, in light of this and other 
reviewer’s comments.  Thank you for the suggestions. 
 
 
